vs
Side-by-side financial comparison of AVALON HOLDINGS CORP (AWX) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
AVALON HOLDINGS CORP is the larger business by last-quarter revenue ($21.5M vs $16.1M, roughly 1.3× Journey Medical Corp). AVALON HOLDINGS CORP runs the higher net margin — -1.7% vs -7.8%, a 6.1% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 21.7%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 6.7%).
Avalon Hill Games Inc. is a game company that publishes wargames and strategic board games. It has also published miniature wargaming rules, role-playing games and sports simulations. It is a subsidiary of Hasbro, and operates under the company's "Hasbro Gaming" division.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
AWX vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.5M | $16.1M |
| Net Profit | $-356.0K | $-1.2M |
| Gross Margin | 17.1% | — |
| Operating Margin | 0.4% | -2.8% |
| Net Margin | -1.7% | -7.8% |
| Revenue YoY | 21.7% | 27.3% |
| Net Profit YoY | 28.4% | -182.0% |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.5M | $16.1M | ||
| Q3 25 | $25.7M | $17.0M | ||
| Q2 25 | $20.3M | $15.0M | ||
| Q1 25 | $16.1M | $13.1M | ||
| Q4 24 | $17.6M | $12.6M | ||
| Q3 24 | $24.2M | $14.6M | ||
| Q2 24 | $23.1M | $14.9M | ||
| Q1 24 | $18.9M | $13.0M |
| Q4 25 | $-356.0K | $-1.2M | ||
| Q3 25 | $1.9M | $-2.3M | ||
| Q2 25 | $274.0K | $-3.8M | ||
| Q1 25 | $-1.5M | $-4.1M | ||
| Q4 24 | $-497.0K | $1.5M | ||
| Q3 24 | $1.8M | $-2.4M | ||
| Q2 24 | $954.0K | $-3.4M | ||
| Q1 24 | $-979.0K | $-10.4M |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 23.7% | — | ||
| Q2 25 | 20.6% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 17.5% | 82.3% | ||
| Q3 24 | 24.6% | 63.9% | ||
| Q2 24 | 22.1% | 56.0% | ||
| Q1 24 | 16.2% | 47.7% |
| Q4 25 | 0.4% | -2.8% | ||
| Q3 25 | 9.1% | -9.0% | ||
| Q2 25 | 3.7% | -19.2% | ||
| Q1 25 | -7.2% | -25.3% | ||
| Q4 24 | -0.8% | 17.7% | ||
| Q3 24 | 9.4% | -19.8% | ||
| Q2 24 | 6.3% | -19.7% | ||
| Q1 24 | -2.7% | -77.4% |
| Q4 25 | -1.7% | -7.8% | ||
| Q3 25 | 7.4% | -13.6% | ||
| Q2 25 | 1.4% | -25.3% | ||
| Q1 25 | -9.3% | -31.0% | ||
| Q4 24 | -2.8% | 12.1% | ||
| Q3 24 | 7.6% | -16.3% | ||
| Q2 24 | 4.1% | -22.6% | ||
| Q1 24 | -5.2% | -80.1% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | — | $-0.17 | ||
| Q1 24 | — | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $38.4M | $31.9M |
| Total Assets | $87.4M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | $24.1M | ||
| Q3 25 | $4.6M | $24.9M | ||
| Q2 25 | $3.7M | $20.3M | ||
| Q1 25 | $1.3M | $21.1M | ||
| Q4 24 | $2.8M | $20.3M | ||
| Q3 24 | $3.9M | $22.5M | ||
| Q2 24 | $3.8M | $23.9M | ||
| Q1 24 | $1.2M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $38.4M | $31.9M | ||
| Q3 25 | $38.7M | $25.9M | ||
| Q2 25 | $36.8M | $19.2M | ||
| Q1 25 | $36.5M | $21.5M | ||
| Q4 24 | $38.0M | $20.1M | ||
| Q3 24 | $38.5M | $10.9M | ||
| Q2 24 | $36.7M | $11.3M | ||
| Q1 24 | $35.7M | $13.0M |
| Q4 25 | $87.4M | $94.6M | ||
| Q3 25 | $90.7M | $85.2M | ||
| Q2 25 | $88.1M | $81.2M | ||
| Q1 25 | $87.6M | $85.0M | ||
| Q4 24 | $86.2M | $80.2M | ||
| Q3 24 | $89.1M | $64.0M | ||
| Q2 24 | $91.7M | $65.2M | ||
| Q1 24 | $90.6M | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.0K | $-6.3M |
| Free Cash FlowOCF − Capex | $-166.0K | — |
| FCF MarginFCF / Revenue | -0.8% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.0K | $-6.3M | ||
| Q3 25 | $1.5M | $-2.4M | ||
| Q2 25 | $3.0M | $-942.0K | ||
| Q1 25 | $-982.0K | $-2.8M | ||
| Q4 24 | $-579.0K | $2.2M | ||
| Q3 24 | $342.0K | $-1.2M | ||
| Q2 24 | $3.2M | $-5.2M | ||
| Q1 24 | $411.0K | $-5.0M |
| Q4 25 | $-166.0K | — | ||
| Q3 25 | $852.0K | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $-1.1M | — | ||
| Q3 24 | $-660.0K | — | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $56.0K | — |
| Q4 25 | -0.8% | — | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 13.5% | — | ||
| Q1 25 | -8.5% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | 12.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 11.07× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 3.35× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AWX
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
